General Rheumatology

Australian researchers perform "target trial emulation" to compare popular drugs

One specific gut microbe may be a major factor

Trial data show rates higher, though still low, with drug versus placebo

Randomized study finds no disparities in biologics prescribing, but questions linger

New "points to consider" document lists early warning signs

Phase III results back potential competitor for pegloticase-methotrexate treatment

Novel agent targets CD40 ligand

Of three major prognostic tools, none hit the mark

New study finds marked risk reduction tied to drugs' urate-lowering effect

Stunning improvement for two patients with rare form of autoimmune myositis

Study finds genetic basis long sought in disabling pansclerotic morphea, leading to effective tx

Familiar biologic halts progression in high-risk patients with just a few painful joints

In separate studies, one old standby and one newer biologic appeared helpful

Disease characteristics, risk factors for complications differ between young and old